← Back to Search

Monoclonal Antibodies

Tislelizumab + SX-682 for Pancreatic Cancer

Phase 2
Led By Eric Christenson, MD
Research Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥18 years
Newly diagnosed with histologically or cytologically proven adenocarcinoma of the pancreas
Screening 3 weeks
Treatment Varies
Follow Up 4 years
Awards & highlights

Study Summary

This trial will test a combo of drugs to see if they're safe & effective for advanced pancreatic cancer after other treatments have failed.

Who is the study for?
Adults over 18 with newly diagnosed, resectable pancreatic adenocarcinoma can join this trial. They must understand and consent to the study, have good performance status (ECOG 0 or 1), adequate organ function, agree to use birth control, and be willing to undergo a tumor biopsy.Check my eligibility
What is being tested?
The trial is testing the safety and effectiveness of Tislelizumab combined with SX-682 in patients who've had prior chemotherapy for metastatic pancreatic cancer. It aims to see how well these drugs work before surgery (neoadjuvant therapy).See study design
What are the potential side effects?
Potential side effects may include allergic reactions to monoclonal antibodies like Tislelizumab, increased risk of infection due to immune system suppression, possible heart rhythm problems (QTc interval changes), lung issues such as pneumonitis or fibrosis.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am 18 years old or older.
I have been recently diagnosed with pancreatic cancer.
I am fully active or can carry out light work.
I am using or willing to use birth control during the study.
My organ and bone marrow functions meet the required levels.
I agree to have a tumor biopsy.
My tumor can be surgically removed.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Immune response rate as assessed by density of intratumoral granzyme B+ CD137+ T cells
Pathologic Response Rate as assessed by number of patients with a grade 0-2 pathologic response
Secondary outcome measures
Disease Free Survival (DFS)
Number of participants experiencing grade 3 or above drug-related toxicities
Overall Survival (OS)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Arm A - Tislelizumab and SX-682Experimental Treatment2 Interventions
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3

Find a Location

Who is running the clinical trial?

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
557 Previous Clinical Trials
32,875 Total Patients Enrolled
BeiGeneIndustry Sponsor
175 Previous Clinical Trials
28,789 Total Patients Enrolled
Syntrix Biosystems, Inc.Industry Sponsor
13 Previous Clinical Trials
782 Total Patients Enrolled

Media Library

Tislelizumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05604560 — Phase 2
Pancreatic Cancer Research Study Groups: Arm A - Tislelizumab and SX-682
Pancreatic Cancer Clinical Trial 2023: Tislelizumab Highlights & Side Effects. Trial Name: NCT05604560 — Phase 2
Tislelizumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05604560 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research project have any unfilled appointments?

"No, this particular medical trial is not currently seeking new patients. That being said, there are 726 other clinical trials that are actively recruiting people right now."

Answered by AI

What are the FDA's thoughts on Arm A - Tislelizumab and SX-682?

"Arm A - Tislelizumab and SX-682 is currently being trialed in Phase 2. While there is evidence that this intervention is safe, its efficacy has not yet been studied."

Answered by AI
~17 spots leftby Sep 2026